Novo Nordisk Expands Production Capacity with $16.5 Billion Catalent Acquisition

The strategic move aims to meet the surging demand for Wegovy and Ozempic, amidst growing competition and global expansion plans.

Novo Nordisk's parent company, Novo Holdings, acquires Catalent for $16.5 billion to boost production of Wegovy and Ozempic.
The deal includes the purchase of three manufacturing sites for $11 billion, enhancing Novo Nordisk's capacity to meet surging demand.
Wegovy's popularity continues to grow, with significant demand in both the US and Europe, where many are willing to pay out-of-pocket.
Novo Nordisk faces competition from Eli Lilly's Zepbound, but remains a dominant player in the obesity and diabetes drug market.
The acquisition aims to address supply shortages and support Novo Nordisk's expansion plans, including into Asia.